Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc.（PCSA）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · PCSA · 截至 2023年12月31日
股东结构概览
18
机构持有人数
▼ 2 vs Q3
$376,475
机构持仓总市值
▲ $26,655 vs Q3
2.27M
总流通股
freeFloat 90.05%
1.13M
13F 申报持股数
▼ 255,338 vs Q3
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
PCSA 最大股东 · 机构持仓
Q4 2023 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
CITADEL ADVISORS LLC pharmaceutical preparations | 315.4K | 1.17% | 1.17% | $105.54M | Feb 14, 2024 | ▲ 149.2K |
VANGUARD GROUP INC pharmaceutical preparations | 234.7K | 86.90% | 86.90% | $78.52M | Mar 11, 2024 | ▼ 109.8K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 122.0K | 45.19% | 45.19% | $40.83M | Feb 13, 2024 | ▼ 30.6K |
UBS GROUP AG pharmaceutical preparations | 80.0K | 29.63% | 29.63% | $26.81M | Feb 9, 2024 | ▲ 79.3K |
SPINNAKER TRUST pharmaceutical preparations | 76.9K | 28.47% | 28.47% | $25.72M | Feb 2, 2024 | NEW |
COASTAL BRIDGE ADVISORS, LLC pharmaceutical preparations | 65.0K | 24.06% | 24.06% | $21.73M | Feb 15, 2024 | ▲ 12.5K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 58.2K | 21.55% | 21.55% | $19.00M | Feb 13, 2024 | ▲ 4.3K |
ROYAL BANK OF CANADA pharmaceutical preparations | 46.3K | 17.15% | 17.15% | $15.00M | Feb 14, 2024 | ▼ 76 |
STATE STREET CORP pharmaceutical preparations | 42.8K | 15.84% | 15.84% | $14.32M | Feb 14, 2024 | — held |
NORTHERN TRUST CORP pharmaceutical preparations | 28.1K | 10.42% | 10.42% | $9.41M | Feb 13, 2024 | ▲ 12.7K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q4 2023 对比上季度
Q4 2023
6
增持
+258.0K 股4
新建仓
首次建仓5
减持
−157.0K 股6
清仓
完全退出净股数变化（前50家）
+101.0K
+258.0K / −157.0K
净新增持仓人
-1
新建 4 个 / 退出 6 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
PCSA 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
13
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Young David Pres. Research & Development | May 29, 2026 | Purchase | 1,786 | $2.57 | $4.6K | 17.1K | Form 4 ↗ |
SKIBSTED RUSSELL Chief Financial Officer | May 29, 2026 | Purchase | 2,292 | $2.57 | $5.9K | 10.8K | Form 4 ↗ |
Ng George K Chief Executive Officer | May 29, 2026 | Purchase | 2,129 | $2.57 | $5.5K | 10.0K | Form 4 ↗ |
Lin Patrick Chief Business - Strategy Off | May 29, 2026 | Purchase | 1,582 | $2.57 | $4.1K | 9.2K | Form 4 ↗ |
Guy Wendy Chief Administrative Officer | May 29, 2026 | Purchase | 1,829 | $2.57 | $4.7K | 9.8K | Form 4 ↗ |
Ng George K Chief Executive Officer | May 15, 2026 | Purchase | 1,843 | $2.97 | $5.5K | 7.8K | Form 4 ↗ |
Young David Pres. Research & Development | May 15, 2026 | Purchase | 1,545 | $2.97 | $4.6K | 15.3K | Form 4 ↗ |
Lin Patrick Chief Business - Strategy Off | May 15, 2026 | Purchase | 1,369 | $2.97 | $4.1K | 7.6K | Form 4 ↗ |
Guy Wendy Chief Administrative Officer | May 15, 2026 | Purchase | 1,583 | $2.97 | $4.7K | 8.0K | Form 4 ↗ |
SKIBSTED RUSSELL Chief Financial Officer | May 15, 2026 | Purchase | 1,984 | $2.97 | $5.9K | 8.5K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Processa Pharmaceuticals, Inc.（PCSA）主要由机构投资者持有，机构持股比例约为 49.9%。公司内部人员持股约 9.95%，散户及公众持股约占剩余的 40.15%。
Processa Pharmaceuticals, Inc. 最大机构股东为 CITADEL ADVISORS LLC，截至 December 31, 2023 持有约 315,410 股，占总流通股的 1.17%。
目前共有 18 家机构持有 PCSA 股票，合计持仓市值约 $376,475，数据来源为最新 SEC 13F 申报。
常见问题
PCSA ownershipProcessa Pharmaceuticals, Inc.（PCSA）主要由机构投资者持有，机构持股约 49.9%。最大股东为 CITADEL ADVISORS LLC，持股比例 1.17%。内部人员持股约 9.95%。数据来源 SEC Form 13F，截至 December 31, 2023。